Are You Speaking the Same Language When Discussing Biomarkers With Your Patients?
Nursing Panel Shares Experiences in Managing Toxicities in Renal Cell Carcinoma
Sarah Yenser Wood, RN, MSN, ANP, AOCNP, leads a nursing panel on adverse event management in renal cell carcinoma.
Older Patients Are Comfortable With Telehealth and Prefer It as an Option
92% of those over 70 say they are comfortable with telehealth.
A Treatment Evolution Is Underway in BRAF V600E–Mutated mCRC
Investigators continue to explore new ways to manage colorectal cancer
with a BRAF V600E mutation.
A Multidisciplinary Approach Improves a Patient’s Experience With Colon Cancer
Early coordination with multiple specialty teams can maximize outcomes and improve quality of life for patients with complex metastatic disease.
Precision Medicine Advances Represent New Paradigm in Cancer Care
Precision medicine is a term that has been in our oncology language for years, but changes are occurring quickly. As oncology nurses, we need to learn about genomics and biomarkers and what precision medicine means for patients’ outcomes.
Perspectives on Best Practices in Caring for Patients With Pancreatic Cancer and Cholangiocarcinoma
Patients with unresectable pancreatic cancers and cholangiocarcinoma face poor prognoses, but systemic treatment continues to evolve.
Oncology Nursing Stories: Off-The-Shelf CAR T Therapy for Acute Lymphoblastic Leukemia
In this episode of The Vitals, Stephanie Jackson, DNP, MSN, RN, AOCNS, BMTCN, discusses the treatment journey of a patient who required multiple lines of therapy for ALL.
FDA Grants Pirtobrutinib Accelerated Approval for Relapsed/Refractory MCL
Pirtobrutinib has been approved for patients with mantle cell lymphoma. The prescribing label comes with warnings for infections, hemorrhage, cytopenias, atrial fibrillation and flutter, second primary malignancies, and embryo-fetal toxicity.
Teclistamab-cqyv Snags Accelerated Approval for Relapsed or Refractory Multiple Myeloma
Patients with multiple myeloma who have already undergone 4 lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody, may now receive treatment with teclistamab-cqyv (Tecvayli).
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
2 Clarke Drive Cranbury, NJ 08512